Quarterly ResultApr 27, 2026, 08:07 AM
RDHL Full-Year 2025 Results; Positive Equity $4.3M; Strategic Deals
AI Summary
RedHill Biopharma reported its full-year 2025 financial results, ending the year with positive equity of $4.3 million, a significant turnaround from a $4.7 million capital deficiency in 2024. The company highlighted strategic transactions, including the formation of Talicia Holdings Inc. and a co-commercialization partnership with Cumberland Pharmaceuticals, and the licensing of RHB-102 (Bekinda) to Hyloris for up to $60 million in potential milestones. RedHill also advanced its R&D pipeline for RHB-204 in Crohn's disease and opaganib in oncology, and secured a $10.5 million court ruling against Kukbo Co. Ltd.
Key Highlights
- Ended 2025 with positive equity of $4.3 million, compared to a $4.7 million capital deficiency in 2024.
- Full-year 2025 revenues were $0.3 million, generated from the Hyloris license for RHB-102.
- Operating loss for 2025 was $7.9 million, compared to $6.5 million for 2024.
- Net income from discontinued operations was $7.7 million in 2025, reversing an $8.6 million loss in 2024.
- Cash balance as of December 31, 2025, was $4.1 million.
- Formed Talicia Holdings Inc. (THI) and partnered with Cumberland Pharmaceuticals, including a $4 million investment for a 30% equity interest.
- Licensed RHB-102 (Bekinda) to Hyloris (ex-North America) for up to $60 million in potential milestone payments plus royalties.
- Awarded over $10.5 million in New York Supreme Court rulings against Kukbo Co. Ltd., now final and eligible for enforcement.